bigdadybry
Member
I recall when AAS were first making it into the mainstream, the negative hype surrounding it included increased prostate cancer risk. I do not recall if this was based on lab rodent data or the assumption the increased DHT adversely affected the prostate.
I am not comparing the two, these are two different products introduced at different times with different test/lab data methodology. I do know there are a multitude of reasons a drug does not hit the market, including but not limited to cancer risk.
I am not comparing the two, these are two different products introduced at different times with different test/lab data methodology. I do know there are a multitude of reasons a drug does not hit the market, including but not limited to cancer risk.